Publications by authors named "Karl Kieburtz"

99Publications

A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.

Mov Disord 2020 Oct 7. Epub 2020 Oct 7.

Clintrex Research Corporation, Sarasota, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28310DOI Listing
October 2020

Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants.

J Parkinsons Dis 2020 ;10(3):1239-1243

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-201973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415719PMC
January 2020

Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.

Mov Disord 2020 06 6;35(6):1055-1061. Epub 2020 Apr 6.

Serina Therapeutics, Inc., Huntsville, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28027DOI Listing
June 2020

Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Neurology 2020 03 26;94(11):481-494. Epub 2020 Feb 26.

From the Department of Neurology (A.J.E.), James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease (L.V.K.), Krembil Research Institute, Toronto Western Hospital, Ontario, Canada; Department of Neurology and Neurosurgery (Z.G.-O.), Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Montreal, Quebec, Canada; Department of Clinical Neurosciences (C.H.W.-G.), John van Geest Centre for Brain Repair, University of Cambridge, UK; Division of Medical Oncology and Hematology (P.L.B.), Princess Margaret Cancer Centre, University Health Network, and Department of Medicine (P.L.B.), University of Toronto, Ontario, Canada; Departments of Medicine (S.M.R.), Pediatrics (S.M.R.), Cell Developmental and Integrative Biology (S.M.R.), and Neurology (D.G.S.), University of Alabama at Birmingham; Department of Clinical and Experimental Medicine (F.M.), University of Messina, Italy; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Edmond J. Safra Program in Parkinson's Disease (A.F., A.P.S., A.E.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.F., A.P.S., A.E.L.); Tomorrow Edition (B.S.), Toronto, Ontario, Canada; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología "José María Ramos Mejía" y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Clinical Genomics Program (M.J.F.), Norman Fixel Institute for Neurological Diseases, McKnight Brain Institute, University of Florida Clinical and Translational Science Institute, Gainesville; Clinical Trials Statistical & Data Management Center (C.S.C.), University of Iowa College of Public Health, Iowa City; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York City, NY; Department of Neurology (R.B.P.), Montreal General Hospital, Quebec; Research Imaging Centre (A.P.S.), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada; Laboratory of Neurogenetics (A.B.S.), National Institute on Aging, NIH, Bethesda, MD; Department of Clinical Neurosciences (R.A.B.), John van Geest Centre for Brain Repair, WT-MRC Cambridge Stem Cell Institute, University of Cambridge, UK; Clinical Trials Coordination Center (K.K.), University of Rochester Medical Center, NY; Department of Neurology and Neuroscience (C.W.O.), Mount Sinai School of Medicine, New York, NY; Clintrex LLC (C.W.O.), Sarasota, FL; Division of Neurosurgery (A.L.), Krembil Neuroscience Institute, Toronto Western Hospital, Ontario, Canada; Department of Neurological Sciences (J.H.K.), Rush University Medical Center, Chicago, IL; Coeruleus Clinical Sciences (J.M.C.), Woodbridge, CT; and Center for Neurodegenerative Science (P.B.), Van Andel Institute, Grand Rapids, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000009107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220234PMC
March 2020

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

Neurology 2020 01 2;94(1):e1-e14. Epub 2019 Dec 2.

From the Biomedical Ethics Unit (A.C.F., A.M., J.K.), McGill University, Montreal, Quebec; Ottawa Hospital Research Institute (D.A.F.), ON, Canada; and Department of Neurology (K.K.), University of Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011691PMC
January 2020

Sample enrichment for clinical trials to show delay of onset in huntington disease.

Mov Disord 2019 02 14;34(2):274-280. Epub 2019 Jan 14.

Department of Biostatistics, Indiana University Fairbanks School of Public Health and School of Medicine, Indianapolis, Indiana, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.27595
Publisher Site
http://dx.doi.org/10.1002/mds.27595DOI Listing
February 2019

Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.

Mov Disord 2018 11 1;33(11):1685-1687. Epub 2018 Nov 1.

Clintrex LLC, Sarasota, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27497DOI Listing
November 2018

Huntington's disease: Current and future therapeutic prospects.

Mov Disord 2018 07 8;33(7):1033-1041. Epub 2018 May 8.

Mount Sinai School of Medicine and Clintrex LLC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27363DOI Listing
July 2018

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Mov Disord 2018 04 24;33(4):520-527. Epub 2018 Mar 24.

King's College, Institute of Psychiatry, Psychology and Neuroscience, London, UK; Centre for Age-Related Diseases, Stavanger.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27345DOI Listing
April 2018

New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.

Mov Disord 2018 07 4;33(6):920-927. Epub 2017 Dec 4.

Clintrex LLC, Sarasota, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27220DOI Listing
July 2018

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Neurology 2017 Dec 15;89(24):2495-2502. Epub 2017 Nov 15.

From F. Hoffman-La Roche, Ltd (S.A.S., G.P., O.S.K., D.T., J.J.S.), Roche Innovation Center, Basel, Switzerland; University of Rochester (P.A., S.M., E.R.D., K.D.K.), NY; University of Iowa (J.D.L., D.R.L.), Iowa City; Massachusetts General Hospital and Harvard Medical School (M.C., S.H.), Boston; CHDI Management/Foundation (C.S.), Princeton, NJ; University of British Columbia, Vancouver, Canada (B.R.L.); and University College London (S.J.T.), UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729794PMC
December 2017

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Neurology 2017 Nov 13;89(19):1959-1969. Epub 2017 Oct 13.

From the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679418PMC
November 2017

The First Frontier: Digital Biomarkers for Neurodegenerative Disorders.

Digit Biomark 2017 Sep-Dec;1(1):6-13. Epub 2017 Jul 4.

Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000477383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015357PMC
July 2017

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Mov Disord 2017 03 24;32(3):319-324. Epub 2017 Feb 24.

Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital and The Edmond J. Safra Program in PD, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359057PMC
March 2017

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

Neurology 2017 Jan 2;88(2):152-159. Epub 2016 Dec 2.

From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.M., K.K., E.A.d.B., K.B., P.C.); Weill Cornell Medical Center (F.B.); Columbia Presbyterian Medical Center (K.M.), New York, NY; Johns Hopkins Medical Center (C.R.), Baltimore, MD; Georgetown University (I.S.), Washington, DC; NINDS (P.G.), Bethesda, MD; Hereditary Neurological Disease Center (W.M.M.), Wichita, KS; The Centre for Movement Disorders (M.G.), Toronto, Canada; Indiana University School of Medicine (J.W.), Indianapolis; Colorado Neurological Institute (R.K.), Englewood; University of Tennessee Health Science Center (M.S.L.), Memphis; London Health Sciences Centre (M.J.), Canada; Massachusetts General Hospital (H.D.R.), Boston; Struthers Parkinson's Center (M.N.), Minneapolis, MN; University of Kansas Medical Center (R.M.D.), Kansas City; Rush University Medical Center (K.M.S.), Chicago, IL; University of Texas Southwestern Medical Center (P.O.), Dallas; University of Michigan (K.C.), Ann Arbor; Wake Forest University (F.W.), Winston-Salem, NC; University of Alberta (W.M.), Edmonton, Canada; University of California Davis (V.L.W.), Sacramento; Westmead Hospital (E. McCusker), Westmead, Australia; Baylor College of Medicine (J.J.), Houston, TX; University of Miami Miller School of Medicine (C.S.), FL; University of South Florida (J.S.-R.), Tampa; Duke University (B.S.), Durham, NC; University of Calgary (O.S.), Canada; Emory University School of Medicine (S.A.F.), Atlanta, GA; Albany Medical College (D.S.H., Eric Molho), NY; University of Cincinnati (F.R.), OH; Mayo Clinic Arizona (J.N.C.), Scottsdale; Butler Hospital (J.H.F.), Providence, RI; Washington University (J.S.P.), St. Louis, MO; Feinstein Institute for Medical Research (A.F.), Manhasset, NY; Georgetown University (K.A.), Washington, DC; University of Florida (R.R., N.R.M.), Gainesville; Johns Hopkins University (R.L.M.), Baltimore, MD; University of Nevada School of Medicine (E.S.F.), Reno; University of British Columbia (L.A.R.), Vancouver, Canada; University of Pittsburgh (V.S.), PA; Ohio State University (S.K.), Columbus; The Cooper University Health System (A.C.), Camden, NJ; Idaho Elks Rehabilitation Hospital (L.S.), Boise, ID; University of Iowa (E.E.), Iowa City; North York General Hospital 1 (S.E.), Toronto, Canada; St. Luke's Hospital (N.D.), Allentown, PA; North York General Hospital 2 (W.L.A.F.), University of Toronto, Canada; Washington Regional Medical Center (A.D.), Fayetteville, AR; Beth-Israel Deaconess Medical Center (S.F.), Boston, MA; NJ Neuroscience Institute (P.H.), Edison; University of California Irvine (N.H.); The University of Alabama at Birmingham (L.S.D.); and Massachusetts General Hospital (M.C.), Harvard Medical School, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224719PMC
January 2017

Communicating with participants during the conduct of multi-center clinical trials.

Clin Trials 2016 12 29;13(6):592-596. Epub 2016 Aug 29.

Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774516665596DOI Listing
December 2016

Moving Parkinson care to the home.

Mov Disord 2016 09 8;31(9):1258-62. Epub 2016 Aug 8.

Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014631PMC
September 2016

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Ann Clin Transl Neurol 2016 Jul 17;3(7):482-94. Epub 2016 May 17.

Institute for Neurodegenerative Disorders (IND) Molecular NeuroImaging LLC (MNI) New Haven Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931714PMC
July 2016

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Int J Neurosci 2017 Mar 27;127(3):276-284. Epub 2016 Jun 27.

e Acorda Therapeutics , Chelsea , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2016.1194274DOI Listing
March 2017

A review of disease progression models of Parkinson's disease and applications in clinical trials.

Mov Disord 2016 07 26;31(7):947-956. Epub 2016 May 26.

Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931998PMC
July 2016

Understanding the 'therapeutic misconception' from the research participant's perspective.

J Med Ethics 2016 Aug 4;42(8):522-3. Epub 2016 May 4.

Department of Neurology, University of Rochester, Rochester, New York, USA Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/medethics-2016-103597DOI Listing
August 2016

Treating neurodegenerative disease before illness: a challenge for the 21st century.

Authors:
Karl Kieburtz

Lancet Neurol 2016 05 21;15(6):540-1. Epub 2016 Mar 21.

University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(16)30001-1DOI Listing
May 2016

Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?

J Med Ethics 2016 08 10;42(8):514-8. Epub 2016 Mar 10.

Department of Neurology, University of Rochester, Rochester, NY, USA Clinical and Translational Science Institute, University of Rochester, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/medethics-2015-103319DOI Listing
August 2016

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Authors:
Kevin Michael Biglan Ira Shoulson Karl Kieburtz David Oakes Elise Kayson M Aileen Shinaman Hongwei Zhao Megan Romer Anne Young Steven Hersch Jack Penney Karen Marder Jane Paulsen Kimberly Quaid Eric Siemers Caroline Tanner William Mallonee Greg Suter Richard Dubinsky Carolyn Gray Martha Nance Scott Bundlie Dawn Radtke Sandra Kostyk Corrine Baic James Caress Francis Walker Victoria Hunt Christine O'Neill Sylvain Chouinard Stewart Factor Timothy Greenamyre Cathy Wood-Siverio Jody Corey-Bloom David Song Guerry Peavy Carol Moskowitz Melissa Wesson Ali Samii Thomas Bird Hillary Lipe Karen Blindauer Frederick Marshall Carol Zimmerman Jody Goldstein Diana Rosas Peter Novak John Caviness Charles Adler Amy Duffy Vicki Wheelock Teresa Tempkin David Richman Lauren Seeberger Roger Albin Kelvin L Chou Brad Racette Joel S Perlmutter Susan Perlman Yvette Bordelon Wayne Martin Marguerite Wieler Blair Leavitt Lynn Raymond Joji Decolongon Lorne Clarke Joseph Jankovic Christine Hunter Robert A Hauser Juan Sanchez-Ramos Sarah Furtado Oksana Suchowersky Mary Lou Klimek Mark Guttman Rustom Sethna Andrew Feigin Marie Cox Barbara Shannon Alan Percy Leon Dure Madaline Harrison William Johnson Donald Higgins Eric Molho Constance Nickerson Sharon Evans Douglas Hobson Carlos Singer Nestor Galvez-Jimenez Kathleen Shannon Cynthia Comella Christopher Ross Marie H Saint-Hilaire Claudia Testa Adam Rosenblatt Penelope Hogarth William Weiner Peter Como Rajeev Kumar Candace Cotto Julie Stout Alicia Brocht Arthur Watts Shirley Eberly Christine Weaver Tatiana Foroud James Gusella Marcy MacDonald Richard Myers Stanley Fahn Clifford Shults

JAMA Neurol 2016 Jan;73(1):102-10

Department of Neuroscience, University of California, San Diego, La Jolla.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2015.2736DOI Listing
January 2016

Advances in clinical trials for movement disorders.

Mov Disord 2015 Sep 26;30(11):1580-7. Epub 2015 Aug 26.

Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.26371
Publisher Site
http://dx.doi.org/10.1002/mds.26371DOI Listing
September 2015

"It is not guaranteed that you will benefit": True but misleading?

Clin Trials 2015 Aug 11;12(4):424-9. Epub 2015 May 11.

Departments of Environmental Medicine and Public Health Sciences, Clinical and Translational Science Institute, University of Rochester, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774515585120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506223PMC
August 2015

Novel methods and technologies for 21st-century clinical trials: a review.

JAMA Neurol 2015 May;72(5):582-8

Department of Neurology, University of Rochester Medical Center, Rochester, New York2Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York4Clinical and Translational Sciences Institute, University of Roche.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.4524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708881PMC
May 2015

Treating idiopathic intracranial hypertension--reply.

JAMA Neurol 2014 Oct;71(10):1327-8

Division of Neuro-Ophthalmology, Roosevelt Hospital, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.2363DOI Listing
October 2014

Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?

J Med Ethics 2015 May 22;41(5):391-7. Epub 2014 May 22.

Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA Department of Neurology, University of Rochester, Rochester, New York, USA Department of Environmental Medicine, University of Rochester, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/medethics-2013-101987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241180PMC
May 2015

The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

JAMA Neurol 2014 Jun;71(6):693-701

Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York14Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351808PMC
June 2014

The idiopathic intracranial hypertension treatment trial: design considerations and methods.

J Neuroophthalmol 2014 Jun;34(2):107-17

Departments of Neurology & Neurotherapeutics and Ophthalmology (DIF), University of Texas Southwestern Medical Center, Dallas, Texas; Departments of Ophthalmology, Neurology, Neurosurgery and Visual Science (SEF), Center for Human Experimental Therapeutics (KK, AS), Department of Biostatistics and Computational Biology and Department of Neurology (MM), University of Rochester School of Medicine and Dentistry, Rochester, New York; Neurology (MW), University of Iowa College of Medicine and Iowa City Veterans Affairs Health Care System, Iowa City, Iowa; National Eye Institute (ES), Bethesda, Maryland; Department of Ophthalmology and Vision Science (JK), University of California Davis Medical Center, Sacramento, California; Departments of Neurology and Ophthalmology (MK), Mount Sinai School of Medicine, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNO.0000000000000114DOI Listing
June 2014

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Mov Disord 2014 May 11;29(6):743-9. Epub 2014 Feb 11.

Clinical Research, The Parkinson's Institute, Sunnyvale, California, USA; Department of Health Research and Policy, Stanford University, Palo Alto, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25814DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656448PMC
May 2014

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

N Engl J Med 2014 Jan;370(4):311-21

From the Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston (R.S.D.); Alzheimer's Disease Cooperative Study, Department of Family and Preventive Medicine (R.G.T., R.R., X.S.), and the Department of Neurosciences (R.G.T., R.R., P.S.A., R.M.), University of California at San Diego, San Diego; Indiana Alzheimer Disease Center, Indiana University (M.F.), and Eli Lilly (E.S., H.L.-S., R.M.) - both in Indianapolis; the Department of Neuropathology, School of Medicine, and the Department of Neuropathology and Neuroscience, School of Pharmacological Science, University of Tokyo, Tokyo (T.I.); Gerontopole, Unité Mixte de Recherche 1027, Centre Hospitalier Universitaire Toulouse, Toulouse, France (B.V.); the Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia (S.J.); and the Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY (K.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1312889DOI Listing
January 2014

Initiating levodopa therapy for Parkinson's disease.

Mov Disord 2014 Mar 9;29(3):430. Epub 2014 Jan 9.

Robert and John M. Bendheim Parkinson and Movement Disorders Center, Mount Sinai School of Medicine, New York, New York, USA; Departments of Neurology and Neuroscience, Mount Sinai Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25805DOI Listing
March 2014

Results of the citalopram to enhance cognition in Huntington disease trial.

Mov Disord 2014 Mar 27;29(3):401-5. Epub 2013 Dec 27.

Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA; Neurological program, Elks Rehab Hospital, Boise, Idaho, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960314PMC
March 2014

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Mov Disord 2014 Feb 3;29(2):263-5. Epub 2013 Dec 3.

Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375545PMC
February 2014

Designing clinical trials for dystonia.

Neurotherapeutics 2014 Jan;11(1):117-27

National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Rm 2225, Bethesda, MD, 20892, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-013-0221-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899487PMC
January 2014

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

N Engl J Med 2013 Jul;369(4):341-50

Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1210951DOI Listing
July 2013

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

Mov Disord 2013 Jul 29;28(8):1064-71. Epub 2013 Apr 29.

Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25364DOI Listing
July 2013

Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions.

Stat Med 2013 Sep 11;32(22):3812-28. Epub 2013 Mar 11.

Division of Biostatistics, University of Texas School of Public Health, 1200 Pressler St, Houston, Texas 77030, U.S.A.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/sim.5778
Publisher Site
http://dx.doi.org/10.1002/sim.5778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884581PMC
September 2013

Research participants' "irrational" expectations: common or commonly mismeasured?

IRB 2013 Jan-Feb;35(1):1-9

Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, USA.

View Article

Download full-text PDF

Source
April 2013

Parkinson's disease: evidence for environmental risk factors.

Mov Disord 2013 Jan 24;28(1):8-13. Epub 2012 Oct 24.

Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25150DOI Listing
January 2013

Sham surgery controls in Parkinson's disease clinical trials: views of participants.

Mov Disord 2012 Sep 23;27(11):1461-5. Epub 2012 Aug 23.

Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703438PMC
September 2012

Comparison of enrollees and decliners of Parkinson disease sham surgery trials.

Mov Disord 2012 Apr 7;27(4):506-11. Epub 2012 Feb 7.

Department of Psychiatry, University of Michigan, Ann Arbor, Michigan 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323770PMC
April 2012

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

Int J Toxicol 2012 Jan-Feb;31(1):58-69. Epub 2012 Jan 20.

Neurology Clinical Trials Unit, Massachusetts General Hospital, 13th Street, Building 149, Room 2274, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1091581811425256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288259PMC
June 2012

TRACK-HD: both promise and disappointment.

Lancet Neurol 2012 Jan 2;11(1):24-5. Epub 2011 Dec 2.

Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(11)70285-XDOI Listing
January 2012

Pharmacologic approaches to the treatment of Huntington's disease.

Mov Disord 2012 Jan 13;27(1):31-41. Epub 2011 Oct 13.

Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23953DOI Listing
January 2012

Milestones in movement disorders clinical trials: advances and landmark studies.

Mov Disord 2011 May;26(6):1003-14

Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23727DOI Listing
May 2011

Advocacy Recruiting for Huntington's Disease Clinical Trials.

PLoS Curr 2011 Apr 12;3:RRN1230. Epub 2011 Apr 12.

Huntington's Disease Drug Works; Evergreen Neuroscience Institute; Northwest Chapter Huntington's Disease Society of America; Huntington's Disease Society of America and University of Rochester Medical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/currents.RRN1230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082401PMC
April 2011

Building capacity across the spectrum of research translation: centers of excellence within the Rochester Clinical and Translational Science Institute.

Clin Transl Sci 2010 Dec;3(6):272-4

The Rochester Clinical and Translational Science Institute, School of Medicine, University of Rochester Medical Center, Rochester, New York, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098049PMC
http://dx.doi.org/10.1111/j.1752-8062.2010.00234.xDOI Listing
December 2010

Discovering neuroprotection in Parkinson's disease, or getting to haphazard.

Authors:
Karl Kieburtz

Mt Sinai J Med 2010 Nov-Dec;77(6):700-6

University of Rochester Medical Center, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/msj.20219DOI Listing
June 2011

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Lancet Neurol 2010 Dec 20;9(12):1164-1172. Epub 2010 Oct 20.

Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA; Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA; Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(10)70254-4DOI Listing
December 2010

Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.

Authors:
Karl Kieburtz

Mov Disord 2011 Jan 5;26(1):37-44. Epub 2010 Oct 5.

University of Rochester Medical Center, Rochester, New York 14620, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23396DOI Listing
January 2011

Defining disease-modifying therapies for PD--a road map for moving forward.

Mov Disord 2010 Sep;25(12):1774-9

Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23288DOI Listing
September 2010

The relationship between uric acid levels and Huntington's disease progression.

Mov Disord 2010 Jan;25(2):224-8

Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.22907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831113PMC
January 2010

ADAGIO misses a beat?

Authors:
Karl Kieburtz

Lancet Neurol 2009 Dec;8(12):1081-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(09)70297-2DOI Listing
December 2009